234 related articles for article (PubMed ID: 29799292)
1. Treatment patterns, adherence, and persistence among psoriasis patients treated with biologics in a real-world setting, overall and by disease severity.
Murage MJ; Anderson A; Casso D; Oliveria SA; Ojeh CK; Muram TM; Merola JF; Zbrozek A; Araujo AB
J Dermatolog Treat; 2019 Mar; 30(2):141-149. PubMed ID: 29799292
[TBL] [Abstract][Full Text] [Related]
2. Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis.
Wu JJ; Pelletier C; Ung B; Tian M
J Med Econ; 2019 Apr; 22(4):365-371. PubMed ID: 30652520
[TBL] [Abstract][Full Text] [Related]
3. Healthcare resource utilization and costs among psoriasis patients treated with biologics, overall and by disease severity.
Murage MJ; Anderson A; Oliveria SA; Casso D; Ojeh CK; Muram TM; Merola JF; Araujo AB
J Med Econ; 2018 Aug; 21(8):745-754. PubMed ID: 29718756
[TBL] [Abstract][Full Text] [Related]
4. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.
Lyu R; Govoni M; Ding Q; Black CM; Kachroo S; Fan T; Ogbonnaya A; Donga P; Hill J; Makin C
Rheumatol Int; 2016 Jan; 36(1):143-53. PubMed ID: 26314368
[TBL] [Abstract][Full Text] [Related]
5. Drug Adherence and Persistence of Patients with Moderate to Severe Psoriasis Treated with Biologic Medications in a US Commercially Insured Population.
Xu C; Teeple A; Wu B; Fitzgerald T; Feldman SR
Dermatology; 2022; 238(3):438-447. PubMed ID: 34710876
[TBL] [Abstract][Full Text] [Related]
6. Real-World Biologic Adherence, Persistence, and Monotherapy Comparisons in US Patients with Psoriasis: Results from IBM MarketScan
Leonardi C; Zhu B; Malatestinic WN; Eastman WJ; Guo J; Murage MJ; Choong CK; Burge R; Blauvelt A
Adv Ther; 2022 Jul; 39(7):3214-3224. PubMed ID: 35570242
[TBL] [Abstract][Full Text] [Related]
7. Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population.
Doshi JA; Takeshita J; Pinto L; Li P; Yu X; Rao P; Viswanathan HN; Gelfand JM
J Am Acad Dermatol; 2016 Jun; 74(6):1057-1065.e4. PubMed ID: 26946986
[TBL] [Abstract][Full Text] [Related]
8. Persistence of treatment with biologics for patients with psoriasis: a real-world analysis of 16 545 biologic-naïve patients from the French National Health Insurance database (SNIIRAM).
Sbidian E; Mezzarobba M; Weill A; Coste J; Rudant J
Br J Dermatol; 2019 Jan; 180(1):86-93. PubMed ID: 29791721
[TBL] [Abstract][Full Text] [Related]
9. Treatment patterns, healthcare resource utilization, and costs in patients with moderate-to-severe psoriasis treated with systemic therapy in Japan: A retrospective claims database study.
Tada Y; Kim H; Spanopoulos D; Habiro K; Tsuritani K; Yamada Y; Mandal A; Zhong Y; Hikichi Y
J Dermatol; 2022 Nov; 49(11):1106-1117. PubMed ID: 35946343
[TBL] [Abstract][Full Text] [Related]
10. A Retrospective Cohort Analysis of Treatment Patterns Over 1 Year in Patients with Psoriasis Treated with Ixekizumab or Guselkumab.
Blauvelt A; Burge R; Gallo G; Charbonneau B; Malatestinic W; Zhu B; Wan F; Lockshin B
Dermatol Ther (Heidelb); 2022 Mar; 12(3):701-714. PubMed ID: 35220545
[TBL] [Abstract][Full Text] [Related]
11. Treatment adherence and persistence of five commonly prescribed medications for moderate to severe psoriasis in a U.S. commercially insured population.
Wu B; Muser E; Teeple A; Pericone CD; Feldman SR
J Dermatolog Treat; 2021 Sep; 32(6):595-602. PubMed ID: 31714168
[TBL] [Abstract][Full Text] [Related]
12. Switching of biologics in psoriasis: Reasons and results.
Honda H; Umezawa Y; Kikuchi S; Yanaba K; Fukuchi O; Ito T; Nobeyama Y; Asahina A; Nakagawa H
J Dermatol; 2017 Sep; 44(9):1015-1019. PubMed ID: 28488283
[TBL] [Abstract][Full Text] [Related]
13. Real-world US healthcare costs of psoriasis for biologic-naive patients initiating apremilast or biologics.
Feldman SR; Pelletier CL; Wilson KL; Mehta RK; Brouillette MA; Smith D; Bonafede MM
J Comp Eff Res; 2019 Jan; 8(1):45-54. PubMed ID: 30387367
[TBL] [Abstract][Full Text] [Related]
14. Drug Survival of Biological Therapies for Psoriasis Treatment in Germany and Associated Costs: A Retrospective Claims Database Analysis.
Mahlich J; Alba A; Hadad LE; Leisten MK; Peitsch WK
Adv Ther; 2019 Jul; 36(7):1684-1699. PubMed ID: 31102203
[TBL] [Abstract][Full Text] [Related]
15. Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.
Garber C; Plotnikova N; Au SC; Sorensen EP; Gottlieb A
J Drugs Dermatol; 2015 Aug; 14(8):846-52. PubMed ID: 26267729
[TBL] [Abstract][Full Text] [Related]
16. Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis.
Bergvall N; Petrilla AA; Karkare SU; Lahoz R; Agashivala N; Pradhan A; Capkun G; Makin C; McGuiness CB; Korn JR
J Med Econ; 2014 Oct; 17(10):696-707. PubMed ID: 25019581
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Real-World Treatment Patterns Among Biologic-Experienced Patients with Psoriasis Treated with Ixekizumab or Secukinumab Over 18 Months.
Blauvelt A; Shi N; Burge R; Somani N; Ridenour TL; Zhu B; Atiya B; Lew CR; Zimmerman NM; Murage MJ
Dermatol Ther (Heidelb); 2021 Dec; 11(6):2133-2145. PubMed ID: 34652590
[TBL] [Abstract][Full Text] [Related]
18. Persistence of second-line biologics in psoriasis after first-line biologic failure: a nationwide cohort study from the French health insurance database (SNDS).
Marcombes C; Penso L; Weill A; Dray-Spira R; Zureik M; Sbidian E
Br J Dermatol; 2023 Oct; 189(5):561-568. PubMed ID: 37479503
[TBL] [Abstract][Full Text] [Related]
19. Real-world health outcomes in adults with moderate-to-severe psoriasis in the United States: a population study using electronic health records to examine patient-perceived treatment effectiveness, medication use, and healthcare resource utilization.
Armstrong AW; Foster SA; Comer BS; Lin CY; Malatestinic W; Burge R; Goldblum O
BMC Dermatol; 2018 Jun; 18(1):4. PubMed ID: 29954363
[TBL] [Abstract][Full Text] [Related]
20. Psoriasis treatment patterns: a retrospective claims study.
Higa S; Devine B; Patel V; Baradaran S; Wang D; Bansal A
Curr Med Res Opin; 2019 Oct; 35(10):1727-1733. PubMed ID: 31081697
[No Abstract] [Full Text] [Related]
[Next] [New Search]
